Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This study is for people with multiple myeloma that has come back or not responded to treatment. It tests a new cell therapy (arlocabtagene autoleucel) combined with other drugs to see if they are safe and work better together. About 147 adults will take part to find the best dos…

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy faulty immune cells causing disease. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not re…

This early-stage trial tests a new treatment called CC-97540, which uses specially engineered immune cells (CAR T cells) to target and calm the immune system in people with multiple sclerosis or myasthenia gravis. The study aims to see if the therapy is safe and tolerable, and to…

This study tests a new treatment called arlocabtagene autoleucel (arlo-cel), a CAR-T cell therapy that targets a protein called GPRC5D on myeloma cells. It is for adults with multiple myeloma that has come back or not responded to treatment, and who have already used lenalidomide…